Our aim is to translate promising science into clinical benefits. Our state-of-the-art R&D laboratories are based in Tianjin, China. We are currently conducting research to develop new medicines in the following disease areas: critical care medicine, oncology, cardiovascular diseases, respiratory and inflammation, neurodegenerative diseases.

Since 2019, we have been working with Australian scientists on many research projects. We have strong interests in the revolutionary biotechnology, including novel pharmaceuticals candidates, new excipient/material, drug delivery technology, digital health, IoT devices, sensors, regenerative medicine.